Nano drug delivery system based on natural cells and derivatives for ischemic stroke treatment

• Published in: Chinese medical journal Vol. 138; no. 16; pp. 1945 - 1960
• Main Authors: Lv, Wei, Liu, Yijiao, Li, Shengnan, Ren, Kewei, Fang, Hufeng, Chen, Hua, Xin, Hongliang
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 20.08.2025; Lippincott Williams & Wilkins Ovid Technologies; Wolters Kluwer
• Subjects: Animals; Blood-Brain Barrier - metabolism; Brain; Disease; Drug delivery systems; Drug Delivery Systems - methods; Drug therapy; Energy consumption; Engineering; Humans; Ischemia; Ischemic Stroke - drug therapy; Ligands; Medical diagnosis; Medical research; Mortality; Nanoparticles; Permeability; Physiology; Polyethylene glycol; Review; Stem cells; Stroke - drug therapy; Tissues; Cell membrane biomimetic; Drug delivery systems; Natural cells and derivatives; Ischemic stroke; Blood-brain barrier; Engineering technology
• ISSN: 0366-6999; 2542-5641; 2542-5641
• DOI: 10.1097/CM9.0000000000003685

Abstract Ischemic stroke (IS) ranks as a leading cause of death and disability globally. The blood-brain barrier (BBB) poses significant challenges for effective drug delivery to brain tissues. Recent decades have seen the development of targeted nanomedicine and biomimetic technologies, sparking substantial interest in biomimetic drug delivery systems for treating IS. These systems are devised by utilizing or replicating natural cells and their derivatives, offering promising new pathways for detection and transport across the BBB. Their multifunctionality and high biocompatibility make them effective treatment options for IS. In addition, the incorporation of engineering techniques has provided these biomimetic drug delivery systems with active targeting capabilities, enhancing the accumulation of therapeutic agents in ischemic tissues and specific cell types. This improvement boosts drug transport and therapeutic efficacy. However, it is crucial to thoroughly understand the advantages and limitations of various engineering strategies employed in constructing biomimetic delivery systems. Selecting appropriate construction methods based on the characteristics of the disease is vital to achieving optimal treatment outcomes. This review summarizes recent advancements in three types of engineered biomimetic drug delivery systems, developed from natural cells and their derivatives, for treating IS. It also discusses their effectiveness in application and potential challenges in future clinical translation.